Search results
Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies
Zacks via Yahoo News· 3 weeks agoEditas (EDIT) reports positive new safety and efficacy data from the RUBY and EdiTHAL studies...
Editas (EDIT) Down 2.3% Since Last Earnings Report: Can It Rebound?
Zacks via Yahoo News· 1 month agoIt has been about a month since the last earnings report for Editas Medicine (EDIT). Shares have...
Editas Medicine (EDIT) Crossed Above the 20-Day Moving Average: What That Means for Investors
Zacks via Yahoo News· 1 year agoEditas Medicine (EDIT) reached a significant support level, and could be a good pick for investors...
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
Zacks via Yahoo News· 2 months agoEditas (EDIT) delivered earnings and revenue surprises of -20.63% and 90.26%, respectively, for the...
Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know
Zacks via Yahoo News· 2 months agoEditas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings...
The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
Zacks via Yahoo News· 2 months agoFor Immediate Release Chicago, IL – May 3, 2024 – Zacks.com announces the list of stocks featured in...
Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down
Zacks via Yahoo News· 2 months agoEditas Medicine, Inc. EDIT incurred a loss of 76 cents per share in the first quarter of 2024, wider...
The Zacks Analyst Blog Highlights CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and...
Zacks via Yahoo News· 2 years agoFor Immediate Release Chicago, IL – October 6, 2022 – Zacks.com announces the list of stocks...
Are Medical Stocks Lagging Editas Medicine (EDIT) This Year?
Zacks via Yahoo News· 1 year agoFor those looking to find strong Medical stocks, it is prudent to search for companies in the group...
Biotech Stock Roundup: BLUE, CRSP & VRTX Get Gene Therapy Nod, ACAD Up on Patent News
Zacks via Yahoo News· 7 months agoIt was a busy week for the biotech sector, with important treatment approvals and other pipeline...